Antibodies and antimatter: the resurgence of immuno-PET.
The completion of the human genome, coupled with parallel major research efforts in proteomics and systems biology, has led to a flood of information on the roles of individual genes and proteins in normal physiologic processes and their disruptions in disease. In practical terms, this information has opened the door to increasingly targeted therapies as specific molecular markers are identified and validated. The ongoing transition from empiric to molecular medicine has engendered a need for corresponding molecular diagnostics, including noninvasive molecular imaging. Convergence of knowledge regarding key biomarkers that define normal biologic processes and disease with protein and imaging technology makes this an opportune time to revisit the combination of antibodies and PET, or immuno-PET.
Wu
Anna M
AM
Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, California 90095-1770, USA. awu@mednet.ucla.edu
D000818:Animals; D000906:Antibodies; D006207:Half-Life; D006801:Humans; D007128:Immunoglobulin Fragments / Q000235:genetics; D049268:Positron-Emission Tomography / Q000379:methods*; D015202:Protein Engineering; D016719:Radioimmunodetection / Q000379:methods*
D000906:Antibodies; D007128:Immunoglobulin Fragments